Cargando…

Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation

Detalles Bibliográficos
Autores principales:	Hanania, Nicola A, Maspero, Jorge F, Halpin, David M G, Jackson, David J, Panettieri, Reynold A, Castro, Mario, Domingo, Christian, Daizadeh, Nadia, Gall, Rebecca, Jacob-Nara, Juby A, Ortiz, Benjamin, Djandji, Michel, Rowe, Paul J, Deniz, Yamo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250327/ https://www.ncbi.nlm.nih.gov/pubmed/35789920 http://dx.doi.org/10.2147/JAA.S354013

Ejemplares similares

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma
por: Papi, Alberto, et al.
Publicado: (2022)

Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils
por: Bleecker, Eugene R., et al.
Publicado: (2023)

Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma
por: Corren, Jonathan, et al.
Publicado: (2023)

Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
por: Corren, Jonathan, et al.
Publicado: (2023)

Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma
por: Corren, Jonathan, et al.
Publicado: (2021)

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL(−1)
por: Rabe, Klaus F., et al.
Publicado: (2022)

Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose
por: Domingo, Christian, et al.
Publicado: (2023)

Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study
por: Fiocchi, Alessandro G., et al.
Publicado: (2023)

Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics
por: Busse, William Walter, et al.
Publicado: (2023)

Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline
por: Bourdin, Arnaud, et al.
Publicado: (2020)

Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study
por: Hopkins, Claire, et al.
Publicado: (2022)

Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
por: Bachert, Claus, et al.
Publicado: (2022)

Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry
por: Gall, Rebecca, et al.
Publicado: (2023)

Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
por: Hellings, Peter W., et al.
Publicado: (2022)

Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials
por: Bachert, Claus, et al.
Publicado: (2022)

Improvement in patient‐reported “taste” and association with smell in dupilumab‐treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS‐24 and SINUS‐52 trials
por: Peters, Anju T., et al.
Publicado: (2022)

AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
por: Siddiqui, Shahid, et al.
Publicado: (2022)

Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma
por: Busse, William W., et al.
Publicado: (2021)

Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design
por: De Prado Gomez, Lucia, et al.
Publicado: (2023)

Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST
por: Maspero, Jorge F., et al.
Publicado: (2021)

The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan
por: Fujieda, Shigeharu, et al.
Publicado: (2020)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Anaphylatoxin C3a receptors in asthma
por: Ali, Hydar, et al.
Publicado: (2005)

Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab
por: van der Veer, Tjeerd, et al.
Publicado: (2021)

Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status
por: Fujieda, Shigeharu, et al.
Publicado: (2021)

Asthma in the elderly: a study of the role of vitamin D
por: Columbo, Michele, et al.
Publicado: (2014)

Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial
por: Maspero, Jorge F, et al.
Publicado: (2023)

Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines
por: Wechsler, Michael E., et al.
Publicado: (2021)

Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps
por: Hopkins, Claire, et al.
Publicado: (2021)

Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function
por: Pavord, Ian D, et al.
Publicado: (2020)

The Role of Dupilumab in Severe Asthma
por: Ricciardolo, Fabio Luigi Massimo, et al.
Publicado: (2021)

Activation of tumor necrosis factor receptor 1 in airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma?
por: Amrani, Yassine, et al.
Publicado: (2000)

Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps
por: Gevaert, Philippe, et al.
Publicado: (2023)

Asthma and COVID: What Are the Important Questions?
por: Panettieri, Reynold A., et al.
Publicado: (2020)

Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease
por: Schneider, Sven, et al.
Publicado: (2023)

Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis
por: Tanaka, Shunya, et al.
Publicado: (2022)

Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials
por: Mullol, Joaquim, et al.
Publicado: (2021)

Dupilumab: a novel treatment for asthma
por: Vatrella, Alessandro, et al.
Publicado: (2014)

Severe pediatric asthma therapy: Dupilumab
por: Ferrante, Giuliana, et al.
Publicado: (2022)

Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation
por: Busse, William W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_12t700lne6bldum9vn65ktrj0m